ABL Bio Registers Patent for Bispecific Antibody Platform Purification Method in South Africa
Purification of Bioactive Peptides Applied with GrabBody-B
ABL Bio announced on the 15th that it has registered a patent in the Republic of South Africa for the purification method of therapeutics applying the Blood-Brain Barrier (BBB) shuttle platform 'Grabody-B'.
![ABL Bio CI. [Image provided by ABL Bio]](http://www.asiae.co.kr/news/img_view.htm?img=2018121106092182389_1544476159.jpg)
With this patent decision, ABL Bio secures the rights to purify bioactive peptides using protein A affinity chromatography applied to therapeutics utilizing Grabody-B until 2040. ABL Bio is currently undergoing patent examinations in 16 countries, including the United States, Europe, China, and Japan, to secure global rights for this purification method.
Grabody-B is a BBB shuttle platform developed by ABL Bio that enhances the permeability of drugs across the BBB. BBB permeability is considered a major challenge in developing treatments for degenerative brain diseases. The BBB is a tissue that protects the brain by preventing harmful substances from entering, but it also restricts the delivery of antibodies to the brain, hindering treatment.
Grabody-B crosses the BBB by binding to the highly brain-expressed receptor IGF1R (Insulin-like Growth Factor 1 Receptor) and delivers therapeutic antibodies into the brain. In preclinical studies, Grabody-B showed improved brain delivery rates of drugs compared to single antibodies without interfering with normal IGF1R-mediated signaling. One pipeline applying Grabody-B is 'ABL301 (SAR446159)', which was licensed to Sanofi in January last year and is currently undergoing Phase 1 clinical trials in the United States.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Lee Sang-hoon, CEO of ABL Bio, stated, "Recently, Roche’s new bispecific antibody 'Trontinemab', which attaches a BBB shuttle to the amyloid beta (Aβ) single antibody 'Gantenerumab'?previously discontinued due to clinical failure?showed positive early results in Phase 1/2 clinical trials. This demonstrates that a BBB shuttle is essential for developing effective treatments for degenerative brain diseases." He added, "As interest in BBB shuttles continues to grow, we will actively pursue securing related patents going forward."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
